The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs.

Abstract:

:The response to lipid-lowering drugs is modified by a number of factors like age, gender, concomitant disease and genetic determinants. Even within homogenous groups of patients, individual responses vary greatly. Until now, no clinical or biochemical parameter exists which predicts whether a subject will respond well to a particular lipid-lowering drug or, in the extreme case, will develop adverse, life-threatening effects (e.g., myositis or rhabdomyolysis). The recent advances in the human genome project promises to have a great impact on our understanding of lipid and lipoprotein metabolism and of the individual response to lipid-lowering drugs. Monogenetic disorders of the lipid metabolism produce severe clinical phenotypes, such as Tangier disease, but have a minor role in the evaluation of cardiovascular risk in the general population. On the other hand, several polymorphisms in genes involved in lipoprotein metabolism (e.g., apolipoprotein E) are associated with the plasma levels of lipoproteins, explaining a substantial fraction of the variance of LDL or HDL concentrations. In combination, the knowledge of these polymorphisms, further variants yet to be discovered and variants within the genes involved in the metabolism of lipid-lowering drugs will in the future allow these drugs to be selected according to the patients needs and thus increase both efficacy and cost-effectiveness of lipid-lowering regimes.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Hoffmann MM,Winkelmann BR,Wieland H,März W

doi

10.1517/14622416.2.2.107

keywords:

subject

Has Abstract

pub_date

2001-05-01 00:00:00

pages

107-21

issue

2

eissn

1462-2416

issn

1744-8042

journal_volume

2

pub_type

杂志文章,评审
  • Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

    abstract::In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.50

    authors: Korol S,Hurlimann T,Godard B,de Denus S

    更新日期:2013-04-01 00:00:00

  • Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications.

    abstract::Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.10

    authors: Bossé Y

    更新日期:2009-04-01 00:00:00

  • Genetics of antipsychotic-induced weight gain: update and current perspectives.

    abstract::Antipsychotic medications are used to effectively treat various symptoms for different psychiatric conditions. Unfortunately, antipsychotic-induced weight gain (AIWG) is a common side effect that frequently results in obesity and secondary medical conditions. Twin and sibling studies have indicated that genetic factor...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.13.207

    authors: Kao AC,Müller DJ

    更新日期:2013-12-01 00:00:00

  • Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.

    abstract:OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.12.1705

    authors: Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

    更新日期:2007-12-01 00:00:00

  • Gastric cancer pharmacogenetics: progress or old tripe?

    abstract::Gastric cancer remains the second most frequent cause of cancer-related mortality. While surgery is traditionally the initial treatment for early-stage disease, the addition of chemotherapy has been shown to significantly increase overall survival and progression-free survival in advanced and metastatic stages of dise...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.88

    authors: Patel JN,Fuchs CS,Owzar K,Chen Z,McLeod HL

    更新日期:2013-07-01 00:00:00

  • Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.

    abstract:AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0046

    authors: Liu N,Irvin MR,Zhi D,Patki A,Beasley TM,Nickerson DA,Hill CE,Chen J,Kimmel SE,Limdi NA

    更新日期:2017-07-01 00:00:00

  • Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

    abstract:AIM:To determine if copy number variants contribute to warfarin dose requirements, we investigated CYP2C9, VKORC1, CYP4F2, GGCX and CALU for deletions and duplications in a multiethnic patient population treated with therapeutic doses of warfarin. PATIENTS & METHODS:DNA samples from 178 patients were subjected to copy...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.156

    authors: Scott SA,Patel M,Martis S,Lubitz SA,van der Zee S,Yoo C,Edelmann L,Halperin JL,Desnick RJ

    更新日期:2012-02-01 00:00:00

  • Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

    abstract:AIMS:The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is still unclear. This study aims to assess the predictive value of DPYD variation with respect to previously described DPYD variants for 5-FU toxicit...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.28

    authors: Amstutz U,Farese S,Aebi S,Largiadèr CR

    更新日期:2009-06-01 00:00:00

  • Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity.

    abstract::The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.6.4.419

    authors: Aubrecht J,Caba E

    更新日期:2005-06-01 00:00:00

  • Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response.

    abstract:AIM:This study evaluated the impact of SULT4A1 gene variation on psychopathology and antipsychotic drug response in Caucasian subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and a replication sample. PATIENTS & METHODS:SULT4A1 haplotypes were determined using SNP data. The r...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.205

    authors: Ramsey TL,Meltzer HY,Brock GN,Mehrotra B,Jayathilake K,Bobo WV,Brennan MD

    更新日期:2011-04-01 00:00:00

  • Implementation of a pharmacogenomic program in a Brazilian public institution.

    abstract::This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0016

    authors: Suarez-Kurtz G,Kovaleski G,Elias AB,Motta V,Wolch K,Emerenciano M,Mansur MB,Palladino AM,Accioly MT,Ferreira M,Gonçalves AA,de Melo AC

    更新日期:2020-06-01 00:00:00

  • Cell-free DNA diagnostics: current and emerging applications in oncology.

    abstract::Liquid biopsy is a noninvasive dynamic approach for monitoring disease over time. It offers advantages including limited risks of blood sampling, opportunity for more frequent sampling, lower costs and theoretically non-biased sampling compared with tissue biopsy. There is a high degree of concordance between circulat...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2018-0174

    authors: Muluhngwi P,Valdes R Jr,Fernandez-Botran R,Burton E,Williams B,Linder MW

    更新日期:2019-04-01 00:00:00

  • Classical twin design in modern pharmacogenomics studies.

    abstract::Response to medication is highly variable, unpredictable and, at times, may be fatal. All drugs are more effective in certain groups of the population while showing no or minimal benefit in other groups. Although the current data on the subject are piecemeal, anecdotal evidence suggests that, in line with other common...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.171

    authors: Rahmioğlu N,Ahmadi KR

    更新日期:2010-02-01 00:00:00

  • Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.

    abstract:AIM:To investigate the role of genetic polymorphisms in glutamatergic and GABAergic genes and their interactions with environmental stressors in antidepressant response. METHODS:A set of 114 SNPs of 34 glutamatergic and GABAergic genes, mainly in promoter and coding regions, were genotyped in 281 Chinese Han major dep...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.1

    authors: Pu M,Zhang Z,Xu Z,Shi Y,Geng L,Yuan Y,Zhang X,Reynolds GP

    更新日期:2013-02-01 00:00:00

  • Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.

    abstract:AIM:To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS:DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitaglipti...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0010

    authors: Jamaluddin JL,Huri HZ,Vethakkan SR

    更新日期:2016-06-01 00:00:00

  • Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians.

    abstract:AIM:No definite factors predict blood pressure response to angiotensin-converting enzyme-inhibitors. The aim of this study was to test the association of gene polymorphisms of the renin-angiotensin-aldosterone system with essential hypertension and anthropometric variables, intermediate phenotypes and gene polymorphism...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,随机对照试验

    doi:10.2217/14622416.9.10.1419

    authors: Filigheddu F,Argiolas G,Bulla E,Troffa C,Bulla P,Fadda S,Zaninello R,Degortes S,Frau F,Pitzoi S,Glorioso N

    更新日期:2008-10-01 00:00:00

  • Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

    abstract:AIMS:The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS:Towards this end, ABCG2 polymorphisms and expression were assessed in DNA an...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.172

    authors: Lemos C,Giovannetti E,Zucali PA,Assaraf YG,Scheffer GL,van der Straaten T,D'Incecco A,Falcone A,Guchelaar HJ,Danesi R,Santoro A,Giaccone G,Tibaldi C,Peters GJ

    更新日期:2011-02-01 00:00:00

  • Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment.

    abstract:AIM:The genetic origin of familial combined hyperlipidemia (FCH) is not well understood. We used microarray profiling of peripheral blood monocytes to search novel genes and pathways involved in FCH. METHODS:Fasting plasma for determination of lipid profiles, inflammatory molecules and adipokines was obtained and peri...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.8.1035

    authors: Llaverias G,Pou J,Ros E,Zambón D,Cofán M,Sánchez A,Vázquez-Carrera M,Sánchez RM,Laguna JC,Alegret M

    更新日期:2008-08-01 00:00:00

  • Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.

    abstract::Pancreatic carcinoma is usually diagnosed late when treatment options are limited and is considered a chemo-resistant malignancy. However, early stage, good performance status and specific patient subgroup are thought to have a more favorable prognosis. Search for novel molecular biomarkers, which could predict treatm...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2018-0073

    authors: Zemanek T,Melichar B,Lovecek M,Soucek P,Mohelnikova-Duchonova B

    更新日期:2019-01-01 00:00:00

  • Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study.

    abstract:BACKGROUND:Essential hypertension arises from the combined effect of genetic and environmental factors. A pharmacogenomics approach could help to identify additional molecular mechanisms involved in its pathogenesis. AIM:The aim of SOPHIA study was to identify genetic polymorphisms regulating blood pressure response t...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.119

    authors: Frau F,Zaninello R,Salvi E,Ortu MF,Braga D,Velayutham D,Argiolas G,Fresu G,Troffa C,Bulla E,Bulla P,Pitzoi S,Piras DA,Glorioso V,Chittani M,Bernini G,Bardini M,Fallo F,Malatino L,Stancanelli B,Regolisti G,Ferri

    更新日期:2014-09-01 00:00:00

  • The genetics of fibromyalgia syndrome.

    abstract::Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.1.67

    authors: Buskila D,Sarzi-Puttini P,Ablin JN

    更新日期:2007-01-01 00:00:00

  • Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.

    abstract::The multi-drug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette (ABC) superfamily of membrane transporters. MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multi-drug resistance,...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.4.397.22747

    authors: Sakaeda T,Nakamura T,Okumura K

    更新日期:2003-07-01 00:00:00

  • Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.

    abstract:AIM:The present study explored the integrative effect of genes encoding methadone pharmacokinetic and pharmacodynamic pathways on methadone maintenance doses in Han Chinese Patients. MATERIALS & METHODS:Genomic DNA was extracted from 321 opioid-dependent patients and 202 healthy controls, and realtime-PCR and PCR-RFLP...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.96

    authors: Hung CC,Chiou MH,Huang BH,Hsieh YW,Hsieh TJ,Huang CL,Lane HY

    更新日期:2011-11-01 00:00:00

  • Beta-adrenergic receptor polymorphisms and drug responses in asthma.

    abstract::Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.2.173

    authors: Taylor DR,Kennedy MA

    更新日期:2002-03-01 00:00:00

  • International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.

    abstract:AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.58

    authors: Karaca S,Bozkurt NC,Cesuroglu T,Karaca M,Bozkurt M,Eskioglu E,Polimanti R

    更新日期:2015-01-01 00:00:00

  • The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.

    abstract::Despite their clearly distinct pathophysiologies, HIV and cancer are diseases whose response to chemotherapy treatment varies substantially amongst patients, in particular for those with prior drug exposure. This has been attributed, in part, to elevated expression of the ABCB1 drug transporter in some patients, which...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.11.84

    authors: Reed K,Parissenti AM

    更新日期:2011-10-01 00:00:00

  • Genetic variation in statin intolerance and a possible protective role for UGT1A1.

    abstract::The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0146

    authors: V Willrich MA,Kaleta EJ,Bryant SC,Spears GM,Train LJ,Peterson SE,Lennon VA,Kopecky SL,Baudhuin LM

    更新日期:2018-01-01 00:00:00

  • Genomic architecture of pharmacological efficacy and adverse events.

    abstract::The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.144

    authors: Chhibber A,Kroetz DL,Tantisira KG,McGeachie M,Cheng C,Plenge R,Stahl E,Sadee W,Ritchie MD,Pendergrass SA

    更新日期:2014-12-01 00:00:00

  • ALK gene alterations in cancer: biological aspects and therapeutic implications.

    abstract::ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. Recently, a shortly accumulated biomedical research clarified the numerous biological processes underlying its ability to support cancer development, growth and pro...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0166

    authors: Palmirotta R,Quaresmini D,Lovero D,Silvestris F

    更新日期:2017-02-01 00:00:00

  • Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment.

    abstract:AIM:The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.18

    authors: Ferraresso M,Turolo S,Belingheri M,Tirelli AS,Cortinovis I,Milani S,Edefonti A,Ghio L

    更新日期:2015-01-01 00:00:00